Recent Company News

• 06:40 AM ET Jul 09, 2026
  

  Basic resources, banks, tech, industrials and retail the top gainers; healthcare, food/beverage, autos and energy the main laggards:

• 02:57 AM ET Jul 09, 2026
  

  StreetAccount Summary - European pre-market trading update

• 01:07 AM ET Jul 09, 2026
  

  Ipsen announces positive topline results from its Phase III BEOND migraine program evaluating Dysport for the prevention of episodic and chronic migraine in adults (€166.00, 0.00)

• 05:14 PM ET Jul 08, 2026
  

  Rhythm Pharmaceuticals discloses NEJM Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity ($114.43, 0.00)

• 02:00 PM ET Jul 06, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 29-Jun

• 10:55 AM ET Jul 06, 2026
  

  StreetAccount M&A Summary: Week of 29-Jun

• 01:03 AM ET Jul 01, 2026
  

  Ipsen to acquire Memo Therapeutics AG for €200M in cash plus deferred milestones for a total potential consideration in excess of €700M (€168.80, 0.00)

• 06:05 AM ET Jun 29, 2026
  

  StreetAccount Macro Headlines:

• 01:03 AM ET Jun 29, 2026
  

  Ipsen acquires Kartos Therapeutics for $450M upfront at closing plus additional milestone payments of up to $1.3B (€162.40, 0.00)

• 01:05 AM ET Jun 16, 2026
  

  IRLAB presents integrated analysis of mesdopetam data at international conference; confirms robust efficacy results in the Phase II studies (SEK 1.20, 0.00)